In short
ZIGAKIBART is being studied in clinical trials for people with IgA nephropathy, a kidney disease. These trials look at whether it can change kidney findings and how safe it is over the long term. The studies include adults who have IgA nephropathy, including people who finished earlier ZIGAKIBART trials.
Key points
- ZIGAKIBART is being studied in clinical trials for IgA nephropathy, a kidney disease. One trial is Phase 2 and looks at changes in IgA deposition in kidney tissue after 1 or 2 years of treatment. Another is Phase 3 and focuses on long-term safety and tolerability in people who completed earlier ZIGAKIBART trials. The studies include adults with IgA nephropathy, and one study specifically follows people who already took part in previous trials. The trial data show that researchers are mainly testing kidney effects and safety over time.
Clinical trials overview
ZIGAKIBART is being investigated in studies for IgA nephropathy, a kidney disease that can affect how the kidneys work over time. The trial data show two authorised interventional studies, one in Phase 2 and one in Phase 3.
Who is being studied
The studies are focused on people with IgA nephropathy, and the brief summary for the Phase 2 trial says it asks whether ZIGAKIBART changes the course of disease in adults with IgAN. The Phase 3 study includes eligible participants who have already completed previous ZIGAKIBART trials, so it follows people who already have experience with the study drug.
The trial records do not provide detailed age limits, sex limits, or other entry rules beyond the population described in the source data.
Trial phases and study design
The Phase 2 study is an interventional study, which means researchers give the study treatment and then observe what happens. It has an enrollment of 32 people and is authorised.
The Phase 3 study is also interventional and is authorised, with an enrollment of 220 people. Its brief summary says the study is open-label, meaning both the participants and the research team know what treatment is being given.
What researchers are measuring
The main outcome in the Phase 2 study is the change in IgA deposition in kidney tissue after 1 or 2 years of ZIGAKIBART treatment, compared with the level before treatment. This tells researchers whether the amount of IgA buildup in the kidney tissue is changing over time.
The Phase 3 study focuses on long-term safety and tolerability. Its primary outcome includes the type, number, seriousness, and relatedness of treatment-emergent adverse events, as well as adverse events of special interest.
Trial status and size
Both studies are listed as authorised in the source data. The Phase 2 trial is smaller, with 32 participants, while the Phase 3 trial is larger, with 220 participants. The different sizes fit the different goals of the studies, with one looking at kidney tissue changes and the other focusing on longer-term safety follow-up.
Key patient terms
IgA nephropathy is the disease being studied in both trials. IgA deposition means IgA buildup in kidney tissue, which is what the Phase 2 study measures. Safety and tolerability mean how well the treatment is handled by the body and whether unwanted health problems happen over time.
Adverse events are health problems seen during a study, and the Phase 3 trial tracks both general adverse events and those of special interest. Open-label means there is no hiding of the treatment assignment in the study.